Jobs
View more job listings or post a job
UC Davis - Equine Analytical Chemistry Program LC/MS CONFIRMATION SUPERVISOR (LABORATORY RESEARCH SUPERVISOR 2)  
Jazz Pharmaceuticals Head of Toxicology
Dow Development Laboratories Formulation Chemist
Genentech Scientist, DMPK
Pliant Therapeutics, Inc. Associate Director/ Director, Formulation Development
AbVision Inc. Research Scientist (Immunology/Cell Biology, all levels available)
Regulus Therapeutics Senior Research Associate/Scientist, Drug Metabolism and Pharmacokinetics
Aligos Therapeutics Principal Research Scientist, DMPK
Post a job

Seminar luncheon

Generating Efficacious Enzyme Therapeutics based on Knowledge Learned From Biocatalytic Pharmaceutical Manufacture


Speakers: Gjalt Huisman, SVP, Strategic Development (Codexis)
Organizers:
Date: 2019-07-26
Time: 11:30-13:30 Pacific Time
Registration fee (USD): Food: $0.
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (1)Almac
Vendor show vendors registered to date: (5)BUCHI Corporation; Cambrex; CoreRx; MicroConstants; PHC former Panasonic Healthcare
Registration: http://www.PBSS.org
Registration deadline:2019-07-25  (it will close sooner if the seating cap is reached)

About the Topic

Over the past 17 years, Codexis has applied its CodeEvolver® protein engineering platform to enable the efficient manufacture of small molecule pharmaceuticals at commercial scale. Recently, learnings from such programs inspired the development of therapeutic enzymes that are stable for function in the upper intestines, or that have been improved for systemic delivery via extension of  serum and lysosomal half-life, and reduced (predicted) immunogenicity. This presentation will highlight technical developments in both areas and provide a perspective on future implementation of this technology in the pharmaceutical industry.


About the Speakers

Dr. Gjalt Huisman is SVP Strategic Development at Codexis Inc. In this role he focuses on applying the companies’ technology to a broad range of application, including the generation of new therapeutic proteins. He received his PhD fromt he University of Groningen, the Netherlands, and was a post-doctoral fellow at Harvard Medical School. He co-authored 45 scientific papers and is a co-inventor on more than 50 patents.


2019-09-13, Biotransformation and Disposition of Larger Molecules: Peptides, Nucleotides, Proteins, mAbs, and ADCs
2019-10-03, Small-Molecule Bioanalytical Method Validation & Regulated Bioanalysis: Fundamentals, the New FDA Guidance and Regulatory Trends
2019-10-18, Physiologically Based Pharmacokinetic (PBPK) Modeling: Fundamentals, Regulatory Guidance & Applications
2019-11-12, Antibody Drug Discovery and Development: Hit Generation, Engineering, Cell-line Development, IND enabling studies, and Biosimilars
2019-12-10, In Vitro Diagnostics, Companion Diagnostics and Precision Medicine
2020-02-11, Drug-Device Combination
2020-05-12, Regulated Large Molecule Bioanalysis: Fundamentals, the New FDA Guidance and Beyond
2020-05-22, No More Undruggables: Unconventional Approaches for Drug Discovery and Design - prodrugs, PROTACS, fragment-based design, directed evolution and beyond
┬ęPharmaceutical & BioScience Society, International; Last Modified: 7/22/2019; Visited: 399; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

UC Davis UC Davis LC/MS Confirmation Supervisor (Lab Rsch Supv 2) Apply Online: http://50.73.55.13/counter.php?id=165482 UC Davis is an AA/EOE
XCELERATE at Biotech Week Boston Driving the Future of the Life Science Industry. Sept. 11 at BCEC. Learn more.
Pacific BioLabs CRO in Bay Area - PK, toxicology, biocompatibility, analytical chemistry, immunogenicity, biomarker analysis, stability studies, sterility, endotoxin
Hypha Discovery mg-g scale synthesis/purification of CYP/non-CYP metabolites including glucuronides. Plus NEW PolyCYPs kits for in-house synthesis of CYP metabolites.
BIOTECH WEEK BOSTON - Sept. 9-12 Access over 5,000 of the most innovative scientific minds & business leaders in Boston and around the world. Learn More.
Submit a Text Ad